China's medical products administrator approved APT Medical (SHA:688617) subsidiary Shenzhen Huitai Medical Device's registration for its disposable magnetoelectric positioning pressure monitoring pulse electric field ablation catheter, according to a Thursday filing with the Shanghai bourse.
The device is intended for the treatment of drug-refractory, recurrent, and symptomatic paroxysmal atrial fibrillation or abnormal electric impulses in the heart.
The device is used with the cardiac pulse electric field ablation device produced by Shanghai Hongtong Industrial.
Shares fell 1% during Thursday's trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments